Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Story Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsWritten by Nathan Reiff. Publication Date: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. A number of promising treatments have shown considerable potential—and with that comes the possibility of significant sales. Two smaller biotech companies are seeing strong share-price momentum thanks to their leading oncology medicines. Besides their therapeutic potential, these drugs could help the firms move beyond penny-stock status and toward long-term profitability. In both cases, challenges remain, making these typical biotech investments high-risk ventures that also have the potential to deliver outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Med-X is gearing up for a possible Nasdaq listing (ticker: MXRX). But the real opportunity is now – before they hit the big stage.
Their all-natural pesticides have outperformed chemical brands in independent lab tests, providing safer solutions without sacrificing results.
With $6.4M in sales in just four years, they're getting ready for the next step. Become a Med-X Shareholder Before Their Nasdaq Plans Unfold Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% during a week when the S&P 500 fell about 1%. That rally added to IOVA's year-to-date (YTD) gains, which have more than doubled shares so far. Still, with a consensus price target of $8.88, Wall Street anticipates further upside—about 71% from current levels. The primary driver behind Iovance's move is its T‑cell immunotherapy, Amtagvi, approved for certain types of melanoma. Amtagvi has been approved in the U.S. since 2024 and is gaining momentum both in sales and in regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL‑2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Amtagvi's broader potential may extend beyond melanoma: the drug received Fast Track Designation from the FDA for non‑small cell lung cancer and could be effective against other tumor types as well. Some of Iovance's outperformance this year also reflects its Q4 2025 earnings report issued in late February, in which the company posted narrower-than-expected losses per share and roughly $5 million in revenue. For the full year, revenue rose about 30% year‑over‑year. Iovance remains a small, roughly $2 billion company and is still regarded as a penny stock. Despite this year's rally, analysts remain cautious: about half of the roughly 12 analyst ratings are Hold or Sell. Risks are elevated—beyond the usual uncertainties that face smaller biotech firms, Amtagvi's personalized nature makes manufacturing costly and complex, which could limit profitability even if demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain bullish: the consensus price target is $13.60, roughly 70% above the stock's current price even after this rally. ImmunityBio's leading product and primary growth driver is Anktiva, a treatment for specific bladder cancers. In February, shares spiked after the European regulator granted the drug conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva generated $113 million in sales last year, a roughly 700% year‑over‑year increase. Like Amtagvi, Anktiva may have potential in other cancer indications, and ImmunityBio is actively exploring additional designations. Despite the dramatic surge over the last several quarters, IBRX remains a speculative and risky investment. IBRX reported a full‑year net loss of $351 million for 2025 as R&D expenses continued to mount. Still, Wall Street analysts appear more bullish on ImmunityBio than on Iovance: six of seven analysts rate the stock a Buy or equivalent.
| 
